 Cancer Gene Therapy Market Insights, Competitive Landscape, and Market Forecast - 2033
The global Cancer Gene Therapy Market is witnessing remarkable growth as breakthroughs in genetic medicine transform the landscape of cancer treatment. Gene therapy offers innovative approaches tha... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global Cancer Gene Therapy Market is witnessing remarkable growth as breakthroughs in genetic medicine transform the landscape of cancer treatment. Gene therapy offers innovative approaches that directly target the genetic mechanisms responsible for cancer development and progression, providing new hope for patients with challenging and advanced malignancies. The increasing shift toward precision medicine, coupled with rapid advancements in biotechnology, is driving widespread interest in gene-based oncology solutions. The global Cancer Gene Therapy Market is valued at US$ 4.6 Bn in 2026 and is projected to reach US$ 9.1 Bn by 2033, growing at a CAGR of 10.20% during the forecast period.Market Insights Cancer gene therapy is emerging as a key pillar of next-generation oncology care. These therapies are designed to modify, replace, or regulate genetic material within cells to combat cancer more effectively than traditional treatment methods. Ongoing progress in molecular biology, genomics, and cell engineering is enabling the development of increasingly sophisticated therapeutic platforms. The market is benefiting from a growing pipeline of clinical-stage products targeting both hematologic cancers and solid tumors. Researchers are leveraging advanced technologies to improve treatment precision, durability, and safety profiles. Furthermore, the expanding number of regulatory approvals and successful clinical outcomes is strengthening confidence among healthcare providers, investors, and patients. As healthcare systems worldwide prioritize personalized treatment strategies, cancer gene therapy is becoming an integral component of modern cancer management, contributing to sustained market expansion. Drivers Several important factors are fueling the growth of the Cancer Gene Therapy Market. The rising incidence of cancer globally remains one of the strongest growth catalysts. As the number of diagnosed cancer cases increases, healthcare providers are seeking innovative therapies capable of delivering improved clinical outcomes. Another major driver is the rapid advancement of gene-editing technologies and genetic engineering platforms. Scientific innovations have enhanced the ability to identify cancer-causing mutations and develop targeted therapies that address specific disease mechanisms. These advancements are accelerating the transition from conventional treatment approaches toward precision oncology. Increasing investment in biotechnology research and development is also contributing significantly to market growth. Pharmaceutical companies, biotechnology firms, and research organizations are dedicating substantial resources to expanding gene therapy pipelines and improving manufacturing capabilities. In addition, growing awareness regarding personalized medicine and the limitations of traditional cancer treatments is encouraging greater adoption of advanced therapeutic alternatives, further supporting market development. Business Opportunity The Cancer Gene Therapy Market presents substantial opportunities for companies operating across the biotechnology and pharmaceutical sectors. The demand for highly targeted treatments is creating favorable conditions for innovation and commercialization. Organizations developing therapies for treatment-resistant cancers, rare malignancies, and genetically defined patient populations are expected to benefit from expanding market demand. Emerging technologies such as gene editing, engineered immune cell therapies, and oncolytic viral therapies are creating new avenues for product differentiation and strategic growth. Companies are increasingly entering partnerships, licensing agreements, and collaborative research initiatives to accelerate product development and market access. The growing need for specialized manufacturing infrastructure also creates opportunities for contract development and manufacturing organizations. As gene therapy programs advance through clinical and commercial stages, demand for scalable production capabilities is expected to increase considerably. Furthermore, advances in genomic testing and biomarker identification are expected to enhance patient selection and treatment effectiveness, creating additional value throughout the healthcare ecosystem. Region Analysis North America continues to dominate the Cancer Gene Therapy Market due to its strong biotechnology industry, advanced healthcare infrastructure, and extensive investment in oncology research. The region benefits from a favorable regulatory environment and a high concentration of clinical trials focused on innovative gene-based therapies. Europe represents another significant market, supported by increasing government funding for life sciences research, growing adoption of personalized medicine, and strong collaboration between academic institutions and industry participants. Continued innovation in cancer treatment is expected to support regional growth. Asia Pacific is rapidly emerging as a major growth hub for cancer gene therapy. Rising healthcare investments, expanding biotechnology capabilities, increasing cancer prevalence, and growing participation in clinical research are contributing to market expansion throughout the region. Meanwhile, Latin America and the Middle East & Africa are experiencing gradual growth as healthcare systems modernize and access to advanced cancer treatments improves. Increasing awareness and investments in oncology care are expected to create new opportunities in these developing markets. Key Players The Cancer Gene Therapy Market features a competitive landscape characterized by continuous innovation and strategic expansion efforts. Leading companies include: • Novartis AG • Gilead Sciences, Inc. • Bristol Myers Squibb Company • Amgen Inc. • Merck KGaA • Pfizer Inc. • Johnson & Johnson • AstraZeneca plc • GlaxoSmithKline plc • CRISPR Therapeutics AG • Intellia Therapeutics, Inc. • Adaptimmune Therapeutics plc • Autolus Therapeutics plc • bluebird bio, Inc. • Genelux Corporation These organizations are actively investing in clinical development, research collaborations, advanced manufacturing technologies, and regulatory initiatives to strengthen their competitive positions. Their efforts are contributing to the rapid advancement of gene therapy solutions across multiple cancer indications. Segmentation By Therapy Type •Immunotherapy •Gene Transfer •Oncolytic Virotherapy •Gene Editing By Vector •Viral Vectors •Non Viral Vectors By Cancer Type •Blood Cancers •Solid Tumors By End-user •Hospitals & cancer centers •Research institutes & labs •Specialty clinics •Biopharma & manufacturing companies By Region •North America •Europe •Asia Pacific •Latin America •Middle East & Africa Table of Contents1. Executive Summary1.1. Global Cancer Gene Therapy Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Cancer Gene Therapy Market Outlook, 2020 - 2033 3.1. Global Cancer Gene Therapy Market Outlook, by Therapy Type, Value (US$ Bn) & Volume (Units), 2020-2033 3.1.1. Immunotherapy 3.1.2. Gene Transfer 3.1.3. Oncolytic Virotherapy 3.1.4. Gene Editing 3.2. Global Cancer Gene Therapy Market Outlook, by Vector, Value (US$ Bn) & Volume (Units), 2020-2033 3.2.1. Viral Vectors 3.2.2. Non Viral Vectors 3.3. Global Cancer Gene Therapy Market Outlook, by End-user, Value (US$ Bn) & Volume (Units), 2020-2033 3.3.1. Hospitals & Cancer Centers 3.3.2. Research Institutes & Labs 3.3.3. Specialty Clinics 3.3.4. Biopharma & Manufacturing Companies 3.4. Global Cancer Gene Therapy Market Outlook, by Cancer Type, Value (US$ Bn) & Volume (Units), 2020-2033 3.4.1. Blood Cancers 3.4.2. Solid Tumors 3.5. Global Cancer Gene Therapy Market Outlook, by Region, Value (US$ Bn) & Volume (Units), 2020-2033 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Latin America 3.5.5. Middle East & Africa 4. North America Cancer Gene Therapy Market Outlook, 2020 - 2033 4.1. North America Cancer Gene Therapy Market Outlook, by Therapy Type, Value (US$ Bn) & Volume (Units), 2020-2033 4.1.1. Immunotherapy 4.1.2. Gene Transfer 4.1.3. Oncolytic Virotherapy 4.1.4. Gene Editing 4.2. North America Cancer Gene Therapy Market Outlook, by Vector, Value (US$ Bn) & Volume (Units), 2020-2033 4.2.1. Viral Vectors 4.2.2. Non Viral Vectors 4.3. North America Cancer Gene Therapy Market Outlook, by End-user, Value (US$ Bn) & Volume (Units), 2020-2033 4.3.1. Hospitals & Cancer Centers 4.3.2. Research Institutes & Labs 4.3.3. Specialty Clinics 4.3.4. Biopharma & Manufacturing Companies 4.4. North America Cancer Gene Therapy Market Outlook, by Cancer Type, Value (US$ Bn) & Volume (Units), 2020-2033 4.4.1. Blood Cancers 4.4.2. Solid Tumors 4.5. North America Cancer Gene Therapy Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033 4.5.1. U.S. Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 4.5.2. U.S. Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 4.5.3. U.S. Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 4.5.4. U.S. Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 4.5.5. Canada Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 4.5.6. Canada Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 4.5.7. Canada Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 4.5.8. Canada Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 4.6. BPS Analysis/Market Attractiveness Analysis 5. Europe Cancer Gene Therapy Market Outlook, 2020 - 2033 5.1. Europe Cancer Gene Therapy Market Outlook, by Therapy Type, Value (US$ Bn) & Volume (Units), 2020-2033 5.1.1. Immunotherapy 5.1.2. Gene Transfer 5.1.3. Oncolytic Virotherapy 5.1.4. Gene Editing 5.2. Europe Cancer Gene Therapy Market Outlook, by Vector, Value (US$ Bn) & Volume (Units), 2020-2033 5.2.1. Viral Vectors 5.2.2. Non Viral Vectors 5.3. Europe Cancer Gene Therapy Market Outlook, by End-user, Value (US$ Bn) & Volume (Units), 2020-2033 5.3.1. Hospitals & Cancer Centers 5.3.2. Research Institutes & Labs 5.3.3. Specialty Clinics 5.3.4. Biopharma & Manufacturing Companies 5.4. Europe Cancer Gene Therapy Market Outlook, by Cancer Type, Value (US$ Bn) & Volume (Units), 2020-2033 5.4.1. Blood Cancers 5.4.2. Solid Tumors 5.5. Europe Cancer Gene Therapy Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033 5.5.1. Germany Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 5.5.2. Germany Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.3. Germany Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 5.5.4. Germany Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 5.5.5. Italy Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 5.5.6. Italy Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.7. Italy Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 5.5.8. Italy Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 5.5.9. France Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 5.5.10. France Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.11. France Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 5.5.12. France Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 5.5.13. U.K. Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 5.5.14. U.K. Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.15. U.K. Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 5.5.16. U.K. Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 5.5.17. Spain Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 5.5.18. Spain Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.19. Spain Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 5.5.20. Spain Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 5.5.21. Russia Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 5.5.22. Russia Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.23. Russia Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 5.5.24. Russia Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 5.5.25. Rest of Europe Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 5.5.26. Rest of Europe Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.27. Rest of Europe Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 5.5.28. Rest of Europe Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 5.6. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Cancer Gene Therapy Market Outlook, 2020 - 2033 6.1. Asia Pacific Cancer Gene Therapy Market Outlook, by Therapy Type, Value (US$ Bn) & Volume (Units), 2020-2033 6.1.1. Immunotherapy 6.1.2. Gene Transfer 6.1.3. Oncolytic Virotherapy 6.1.4. Gene Editing 6.2. Asia Pacific Cancer Gene Therapy Market Outlook, by Vector, Value (US$ Bn) & Volume (Units), 2020-2033 6.2.1. Viral Vectors 6.2.2. Non Viral Vectors 6.3. Asia Pacific Cancer Gene Therapy Market Outlook, by End-user, Value (US$ Bn) & Volume (Units), 2020-2033 6.3.1. Hospitals & Cancer Centers 6.3.2. Research Institutes & Labs 6.3.3. Specialty Clinics 6.3.4. Biopharma & Manufacturing Companies 6.4. Asia Pacific Cancer Gene Therapy Market Outlook, by Cancer Type, Value (US$ Bn) & Volume (Units), 2020-2033 6.4.1. Blood Cancers 6.4.2. Solid Tumors 6.5. Asia Pacific Cancer Gene Therapy Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033 6.5.1. China Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 6.5.2. China Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.3. China Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 6.5.4. China Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 6.5.5. Japan Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 6.5.6. Japan Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.7. Japan Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 6.5.8. Japan Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 6.5.9. South Korea Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 6.5.10. South Korea Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.11. South Korea Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 6.5.12. South Korea Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 6.5.13. India Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 6.5.14. India Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.15. India Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 6.5.16. India Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 6.5.17. Southeast Asia Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 6.5.18. Southeast Asia Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.19. Southeast Asia Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 6.5.20. Southeast Asia Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 6.5.21. Rest of SAO Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 6.5.22. Rest of SAO Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.23. Rest of SAO Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 6.5.24. Rest of SAO Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 6.6. BPS Analysis/Market Attractiveness Analysis 7. Latin America Cancer Gene Therapy Market Outlook, 2020 - 2033 7.1. Latin America Cancer Gene Therapy Market Outlook, by Therapy Type, Value (US$ Bn) & Volume (Units), 2020-2033 7.1.1. Immunotherapy 7.1.2. Gene Transfer 7.1.3. Oncolytic Virotherapy 7.1.4. Gene Editing 7.2. Latin America Cancer Gene Therapy Market Outlook, by Vector, Value (US$ Bn) & Volume (Units), 2020-2033 7.2.1. Viral Vectors 7.2.2. Non Viral Vectors 7.3. Latin America Cancer Gene Therapy Market Outlook, by End-user, Value (US$ Bn) & Volume (Units), 2020-2033 7.3.1. Hospitals & Cancer Centers 7.3.2. Research Institutes & Labs 7.3.3. Specialty Clinics 7.3.4. Biopharma & Manufacturing Companies 7.4. Latin America Cancer Gene Therapy Market Outlook, by Cancer Type, Value (US$ Bn) & Volume (Units), 2020-2033 7.4.1. Blood Cancers 7.4.2. Solid Tumors 7.5. Latin America Cancer Gene Therapy Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033 7.5.1. Brazil Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 7.5.2. Brazil Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 7.5.3. Brazil Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 7.5.4. Brazil Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 7.5.5. Mexico Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 7.5.6. Mexico Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 7.5.7. Mexico Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 7.5.8. Mexico Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 7.5.9. Argentina Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 7.5.10. Argentina Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 7.5.11. Argentina Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 7.5.12. Argentina Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 7.5.13. Rest of LATAM Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 7.5.14. Rest of LATAM Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 7.5.15. Rest of LATAM Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 7.5.16. Rest of LATAM Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 7.6. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Cancer Gene Therapy Market Outlook, 2020 - 2033 8.1. Middle East & Africa Cancer Gene Therapy Market Outlook, by Therapy Type, Value (US$ Bn) & Volume (Units), 2020-2033 8.1.1. Immunotherapy 8.1.2. Gene Transfer 8.1.3. Oncolytic Virotherapy 8.1.4. Gene Editing 8.2. Middle East & Africa Cancer Gene Therapy Market Outlook, by Vector, Value (US$ Bn) & Volume (Units), 2020-2033 8.2.1. Viral Vectors 8.2.2. Non Viral Vectors 8.3. Middle East & Africa Cancer Gene Therapy Market Outlook, by End-user, Value (US$ Bn) & Volume (Units), 2020-2033 8.3.1. Hospitals & Cancer Centers 8.3.2. Research Institutes & Labs 8.3.3. Specialty Clinics 8.3.4. Biopharma & Manufacturing Companies 8.4. Middle East & Africa Cancer Gene Therapy Market Outlook, by Cancer Type, Value (US$ Bn) & Volume (Units), 2020-2033 8.4.1. Blood Cancers 8.4.2. Solid Tumors 8.5. Middle East & Africa Cancer Gene Therapy Market Outlook, by Country, Value (US$ Bn) & Volume (Units), 2020-2033 8.5.1. GCC Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 8.5.2. GCC Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.3. GCC Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 8.5.4. GCC Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 8.5.5. South Africa Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 8.5.6. South Africa Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.7. South Africa Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 8.5.8. South Africa Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 8.5.9. Egypt Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 8.5.10. Egypt Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.11. Egypt Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 8.5.12. Egypt Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 8.5.13. Nigeria Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 8.5.14. Nigeria Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.15. Nigeria Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 8.5.16. Nigeria Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 8.5.17. Rest of Middle East Cancer Gene Therapy Market Outlook, by Therapy Type, 2020-2033 8.5.18. Rest of Middle East Cancer Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.19. Rest of Middle East Cancer Gene Therapy Market Outlook, by End-user, 2020-2033 8.5.20. Rest of Middle East Cancer Gene Therapy Market Outlook, by Cancer Type, 2020-2033 8.6. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Novartis AG 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Gilead Sciences, Inc. 9.4.3. Bristol Myers Squibb Company 9.4.4. Amgen Inc. 9.4.5. Merck KGaA 9.4.6. Pfizer Inc. 9.4.7. Johnson & Johnson 9.4.8. AstraZeneca plc 9.4.9. GlaxoSmithKline plc 9.4.10. CRISPR Therapeutics AG 9.4.11. Intellia Therapeutics, Inc. 9.4.12. Adaptimmune Therapeutics plc 9.4.13. Autolus Therapeutics plc 9.4.14. bluebird bio, Inc. 9.4.15. Genelux Corporation 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
Fairfield Market Research社の 医薬品・バイオテクノロジー分野 での最新刊レポート
本レポートと同じKEY WORD（cancer）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
